Transferable Exclusivity Extension Vouchers Are Viable In Europe, But Back Up Required
A new study shows that transferable exclusivity extension vouchers are the best way of incentivizing antibiotic development in Europe. However, investors caution that other strategies must also be considered.
You may also be interested in...
A European public health NGO has disputed the suggestion that a transferable exclusivity extension is the answer to the lack of innovative antimicrobial drugs in company pipelines.
Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.
IMC, the R&D-based pharmaceutical industry association in Canada, says the guideline will “exacerbate an already unpredictable regulatory environment.”